This highlight article describes three Alzheimer's disease (AD) studies presented at the 5 th General Meeting of the International Proteolysis Society that address enzymatic mechanisms for producing neurotoxic b-amyloid (Ab) peptides. One group described the poor kinetics of BACE 1 for cleaving the wild-type (WT) b-secretase site of APP found in most AD patients. They showed that cathepsin D displays BACE 1-like specificity and cathepsin D is 280-fold more abundant in human brain than BACE 1. Nevertheless, as BACE 1 and cathepsin D show poor activity towards the WT b-secretase site, they suggested continuing the search for additional b-secretase(s). The second group reported cathepsin B as an alternative b-secretase possessing excellent kinetic efficiency and specificity for the WT b-secretase site. Significantly, inhibitors of cathepsin B improved memory, with reduced amyloid plaques and decreased Ab(40/42) in brains of AD animal models expressing amyloid precursor protein containing the WT b-secretase site. The third group addressed isoaspartate and pyroglutamate (pGlu) posttranslational modifications of Ab. Results showed that cathepsin B, but not BACE 1, efficiently cleaves the WT b-secretase isoaspartate site. Furthermore, cyclization of N-terminal Glu by glutaminyl cyclase generates highly amyloidogenic pGluAb(3-40/42). These presentations suggest cathepsin B and glutaminyl cyclase as potential new AD therapeutic targets.
Introduction
This article reports on presentations made by three independent groups led by Schechter, Hook, and Demuth on Alzheimer's disease (AD) enzyme drug targets reported at the 5 th General Meeting of the International Proteolysis Society (IPS) held in Patras, Greece, on October 20-24, 2007 . Together these studies challenge the current hypothesis that BACE 1 is the predominant b-secretase responsible for the processing of the amyloid precursor protein (APP). These presentations showed that (a) cathepsin D displays BACE 1-like specificity and is much more abundant than BACE 1 in the brain, yet since both enzymes cleave the wild-type b-site sequence very slowly it is necessary to search for additional bsecretase(s), (b) cathepsin B displays highly efficient processing of the WT b-secretase site of APP expressed in the majority of AD patients, and (c) cathepsin B and glutaminyl cyclase participate in the production of posttranslationally modified forms of Ab consisting of isoaspartate (isoAsp)1-Ab and the highly amyloidogenic pyroglutamate (pGluA)b(3-40/42). The authors of this paper represent each of the three research groups.
b-Amyloid of Alzheimer's disease
Abnormal accumulation of neurotoxic b-amyloid (Ab) peptides is a significant factor in the development of AD, and thought to be the likely cause of memory and cognitive loss in this disease condition (Iversen et al., 1995; Sisodia, 1999; Selkoe, 2001; Gandy et al., 2003) . Neuropathological examination of brains from AD patients reveals the accumulation of secreted Ab peptides in extracellular amyloid plaques that are involved in neuronal loss in brain regions (hippocampus and cortex) responsible for memory and cognitive functions. The majority of AD patients are afflicted with sporadic AD that is not linked to genetic mutations (Blennow et al., 2006; Turner, 2006) . A smaller portion of AD patients possess familial forms of AD with inherited genetic mutations, especially those mutations in APP and presenilins that result in increased Ab production and memory deficit when overexpressed in transgenic mouse models of AD (Price and Sisodia, 1998; Masliah and Rockenstein, 2000; Dodart et al., 2002) . Notably, abnormal accumulation of Ab occurs in sporadic and familial AD patients and, therefore, Ab represents a biochemical hallmark of the disease condition. Clearly, strategies to reduce Ab production will facilitate development of therapeutic agents for this devastating disease for which currently there is no effective drug treatment. Ab peptides are generated by proteolytic processing of the APP in secretory vesicles that undergo axonal transport from the neuronal cell body to nerve terminals, where Ab is secreted. Extracellular Ab peptides accumulate as oligomers and aggregates in amyloid plaques, and cause loss of memory in Alzheimer's disease. Cleavage at the N-terminus of Ab within APP is achieved by proteases known as b-secretases, and cleavage at the Ctermini of Ab within APP is achieved by g-secretases. Proteolytic processing by b-and g-secretases results in Ab peptides of 40 and 42 residues, known as Ab and . In addition, APP can be modified to contain isoaspartate (isoAsp) residues, which generates Ab containing isoAsp, isoAb(40/42). Moreover, Ab can be truncated and the terminal glutamate residue modified to pyroglutamate (pGlu) to form pGluAb(3-40/42). The bsecretases that produce these various forms of Ab and the enzyme which generates pGlu are the subject of this report.
b-Amyloid production by proteolytic processing of APP Ab peptides are generated in neuronal secretory vesicles by proteolytic cleavage of the APP by proteases, called b-secretase and g-secretase that cleave at the N-terminus and variant C-termini of Ab within APP, respectively, resulting in Ab of 40 or 42 amino acids (Ab40 and Ab42, respectively) (Figure 1 ). Because the N-termini of Ab40 and Ab42 are identical, development of inhibitors that reduce cleavage of APP at the b-secretase site are likely to be effective for reducing Ab peptide forms with alleviation of neurodegeneration and memory deficit. The APP in the vast majority of AD patients possesses the wild-type b-secretase site sequence.
Production of Ab peptides involves cleavage of the b-secretase site that is located in the soluble intracellular environment, while cleavage at the g-secretase site occurs within a transmembrane domain of the APP precursor protein (Selkoe, 2004; Haass and Selkoe, 2007) . Proteolytic processing of the g-secretase site, within the transmembrane domain, has been demonstrated in detail by studies of the presenilin g-secretase complex in membranes (Selkoe and Wolfe, 2007) . Significantly, APP in the regulated secretory vesicles (RSVs) APP is present as a fully soluble protein (Tezapsidis et al., 1998) , with secretion of full-length APP from RSVs (Efthimiopoulos et al., 1996) . These studies have in large part been conducted in studies of APP and Ab production in the constitutive secretory pathway. Importantly, the major portion of secreted, extracellular Ab peptides is produced in the regulated secretory pathway (Tezapsidis et al., 1998) . In the RSVs, APP is also present as a fully soluble protein.
The full-length soluble APP, thus, has b-and g-secretease sites accessible for proteolytic cleavage. The approach by the Hook laboratory for examining APP processing in the RSVs for producing the majority of extracellular Ab peptide is unique in the field (Hook et al., 2002 (Hook et al., , 2005 , since most studies have examined Ab peptide in the constitutive secretory pathway. The secretory vesicles of the regulated secretory pathway are distinct from those of the constitutive secretory pathway (Lodish et al., 1999) . Clearly, in the RSVs, the soluble and transmembrane orientation of APP allows its proteolytic processing by b-and g-secretases.
According to the amyloid hypothesis, proteolytic processing of human brain APP (Selkoe, 2001 ) preferentially generates Ab 1-40 and to a minor degree Ab 1-42. Both peptides have been believed to initiate aggregation and later deposition in the neuritic plaques characteristic for AD (Findeis, 2007) . In contrast, several studies recently clarified that Ab 1-40 has neuroprotective functions (McGowan et al., 2005; Kim et al., 2007) . In addition, the postmortem analysis of brain samples from sporadic Alzheimer and Down syndrome patients revealed many more Ab species whose profiles differ from that in commonly used AD animal models (Roher et al., 1993; Kuo et al., 1997; Saido, 1998) .
Most abundant among these APP-derived peptides are the isoAsp1-Ab and the pGlu3-Ab species (Roher et al., 1993; Saido, 1998; Shimizu et al., 2000) . The isoAspAb and also pGlu-Ab can make up more than 50% of all amyloid, depending on the site of deposition or on the soluble Ab fraction of the brain (Roher et al., 1993; Piccini et al., 2005) . In contrast to all other Ab species, pGlu-Ab aggregates much faster (He and Barrow, 1999) and also seeds the oligomerization and fibrillation process of the full-length Ab species . Abundant accumulation of Ab species also occurs in brains of cognitive normal elderly patients, without signs of neuronal dysfunction. However, the most prominent species found in these individuals are the amyloid peptides Ab1-40 and Ab1-42, but not the pGlu3-Ab species (Piccini et al., 2005) . The proposal that the BACE 1 product Ab1-40 is neuroprotective, combined with the high abundance of N-truncated and pyroglutamated Ab peptides, which correlate to deposition markers and the severity of dementia, supports the hypothesis that there may be different pathways of APP turnover which trigger formation of different Ab peptide species (Kim et al., 2007; Maeda et al., 2007) .
For these reasons, the b-secretase activity that cleaves the wild-type b-secretase site in APP must be determined for effective b-secretase inhibitors to be developed for the majority of the AD population.
Enzymatic and kinetic properties of proteases for cleaving the wild-type b-secretase site of APP: cleavage-site specificity of proteases
The specificity for peptide substrate cleavage by proteases involves a large active site divided into subsites, using the model and nomenclature of Schechter and Berger (1967) . This model describes interactions of the pro- shows an active site of six subsites, termed S1 to S3 and S19 to S39. Subsites are located on both sides of the catalytic site and are numbered from this point in either direction. The positions of amino acid residues of the hexapeptide substrate are counted from the point of cleavage and thus have the same numbering as the subsites they occupy (P1 to P3 and P19 to P39). Cleavage always occurs between P1 and P19 (Schechter and Berger, 1967) . (B) P3 to P39 residues at the wild-type bsecretase cleavage site. Cleavage of the wild-type site b-secretase site of APP occurs between Met-xAsp which represents the P1-P19 residues. The Val-Lys-Met residues represent the P3, P2 and P1 residues, respectively; the Asp-Ala-Glu residues are the P19, P29 and P39 residues, respectively. tease with the substrate amino acids flanking the cleavage site (Figure 2A ). The amino acids forming the cleaved peptide bond are termed P1-xP19, with residues at the N-terminal and C-terminal sides of the cleavage site indicated as P1, P2« and P19, P29«, respectively. The protease active site is viewed as a series of subsites (S1, S2« and S19, S29«) each accommodating one amino acid residue of the substrate. Protease subsites interact with the polypeptide backbone and with side chains of amino acids of the substrate.
Multiple points of interactions in several subsites are essential for obtaining the high association constants necessary for efficient biological function. Within the large active site certain subsites (close or remote from the catalytic site) play a major role in determining specificity (Schechter and Berger, 1967; Schechter, 2005) . For example, the S1 subsite of trypsin has a clear preference for binding to basic P1 residues consisting of lysine or arginine (Halfon et al., 2004) . In papain (Schechter and Berger, 1968) and the cysteine cathepsins (Rawlings and Barrett, 2004) , specificity is determined mainly by the hydrophobic S2 subsite that prefers binding to hydrophobic P2 residues. The specificity and biological activity of caspases is determined by both S1 and S4 remote from the catalytic site (Nicholson and Thornberry, 1997) . Generally, the P1 to P3 residues are important for protease selectivity for cleavage sites, based on interaction with S1 to S3 subsites of the protease. Therefore, cleavage site-specific assays often incorporate the native P1 to P3 residues, or longer extensions of the peptide substrate.
Evaluation of the P2-P1 residues at the wild-type and Swedish mutant b-secretase cleavage sites At the wild-type b-secretase site of APP, the -P3-P2-P1-xP19-P29-P39-residues are Val-Lys-Met-xAsp-AlaGlu-( Figure 2B ). This wild-type b-secretase site is expressed by the majority of AD patients, and, therefore, represents a key cleavage event for production of neurotoxic Ab. Interestingly, a mutant b-secretase site expressed in an extended Swedish family (Citron et al., 1992) results in elevated production of Ab in these patients, and transgenic mice expressing the human Swedish mutant APP show elevated levels of Ab (Hsiao et al., 1996) . The Swedish mutant P2-P1 residues consist of -that substitute for the wild-type P2-P1 resiAsn Leu dues of Lys-Met. It is important to realize that the amino acids at the Swedish mutant compared to the wild-type b-secretases site differ in chemical properties. A change in the chemical properties of the amino acid side chains may define distinct substrate preferences by the protease.
Notably, the wild-type Lys (lysine) residue at the P2 position is a positively charged hydrophilic residue, but the Swedish mutant Asn (asparagine) residue is an uncharged amino acid. The charged and uncharged properties of Lys and Asn, respectively, at the P2 position may be recognized by different proteases. The P2 residue that interacts with the S2 subsite of proteases is known to be an important determinant of substrate specificity for many proteases, such as the cysteine cathepsins (Rawlings and Barrett, 2004) . Based on the different charged property of the P2 residue of the wild-type site compared to uncharged P2 residue of the Swedish mutant b-secretase site, it is possible that different proteases may cleave the wild-type b-secretase site compared to the Swedish mutant b-secretase site.
Kinetic properties of protease enzymes for polypeptide substrates
Kinetic properties of enzymes are studied by measuring their catalytic efficiency (Berg et al., 2002; Voet and Voet, 2004) . The ratio k cat /K m represents the rate of hydrolysis at infinite dilution of the substrate (Schechter, 1970) . In general, higher values of k cat /K m indicate greater enzymatic performance towards the substrate (Berg et al., 2002; Voet and Voet, 2004) . Active proteases usually have k cat /K m values that range between tens of thousands to a few millions.
These kinetic properties should be assessed in studies of proteases with b-secretase activity to identify those that possess the greatest efficiency for b-secretase cleaving activity. Because cleavage of a peptide bond may occur by several proteases, inhibition of the protease with the highest catalytic efficiency is likely to be most effective for reducing cellular Ab.
Overview of the presentations
The presentations by the Schechter, Hook, and Demuth groups together implicate new b-secretase mechanisms and posttranslational modifying enzymatic mechanisms for the production of Ab peptide forms. The Schechter group demonstrates that human cathepsin D displays BACE 1-like b-secretase specificity, that cathepsin D is more abundant than BACE 1 in the brain, and that bsecretase activity observed in brain extracts at pH 3.8 is mainly due to cathepsin D, which indicates the need to search for additional b-secretase candidate(s) (Schechter and Ziv, 2008) .
The Hook group showed that cathepsin B efficiently cleaves the wild-type b-secretase site (Hook et al., 2005) , and cathepsin B is co-localized with Ab peptides in regulated secretory vesicles (Hook et al., 2005) that provide the majority of extracellular Ab that accumulates in AD. Moreover, inhibitors of cathepsin B improve memory, with reduction of brain Ab and amyloid plaques, in the London APP mouse model of AD expressing the wildtype b-secretase site of APP (Hook et al., 2008) . These inhibitors also reduced Ab in the guinea pig animal model that expresses APP containing the wild-type b-secretase site (Hook et al., 2007a,b) . These findings support cathepsin B as a new b-secretase target for drugs to reduce Ab that contributes to memory deficit in AD.
The Demuth group discussed the production of posttranslationally modified Ab forms in AD brain, consisting of isoaspartate (isoAsp) Ab, isoAb(40/42), and N-terminal truncated peptides including the pyroglutamate (pGlu) modified form of truncated Ab, pGluAb(3/11-40/42). Evidence was provided that cathepsin B, but not BACE 1, efficiently cleaves the wild-type b-secretase site containing isoAsp and that glutaminyl cyclase catalyzes the formation of pGlu to produce pGluAb(3/11-40/42). These findings independently confirmed cathepsin B as a possible drug target to reduce Ab production, and also suggests glutaminyl cyclase as a new drug target for inhibiting the production of pGluAb(3/11-40/42) peptide forms.
Properties of BACE 1 and cathepsin D indicate the need to search for additional b-secretase candidate(s) (presented by I. Schechter)
BACE 1 fulfills many criteria for the b-secretase that cleaves at the b-site of APP (Vassar et al., 1999; Lin et al., 2000; Wolfe, 2006 ), yet it has some problems that are described below (Schechter and Ziv, 2008) .
Poor kinetic properties of BACE 1 for the wild-type b-secretase site BACE 1 cleaves the Swedish mutant b-secretase site sequence of APP much better than the wild-type bsecretase sequence present in the worldwide AD population. BACE 1 activity for the wild-type b-site is extremely low, cleaving it with very low k cat /K m values reported as 40 M -1 s -1 (Lin et al., 2000) and 62 M -1 s -1 (Shi et al., 2001) . Proteases acting on relevant substrates usually have k cat /K m values that range between tens of thousands to a few millions (Dunn and Hung, 2000) .
BACE 1 is a membrane-bound enzyme and the kinetic studies described above (Lin et al., 2000; Shi et al., 2001) were performed in vitro using soluble BACE 1. It has been argued that enzymes anchored in the cell membrane might exhibit reduced activity when freed in solution. TACE is a membrane-bound enzyme like BACE 1, and in vivo it cleaves the precursor tumor necrosis factor a (TNF-a) that is a membrane-bound protein like APP. Yet in vitro, TACE cleaves a peptide spanning the cleavage site of the precursor TNF-a with k cat /K m of 1.8=10 (Turner et al., 2001 ). This peptide differs from the wild-type b-secretase site octapeptide sequence (P4-P49) in 7 out of 8 amino acid residues. These findings suggest that BACE 1 acts on yet unknown substrate(s), and that its cleavage of the wild-type b-secretase site of APP may be a physiological aberration.
Gene knockout experiments in rodents and corresponding genetic defects in human may reveal different phenotype(s)
Several BACE 1 knockout studies conducted in mice expressing human APP show that the absence of BACE 1 reduces Ab formation (Cai et al., 2001; Luo et al., 2001 , Roberds et al., 2001 . These important findings support BACE 1 as a b-secretase. Yet studies in other systems show that gene knockout experiments in rodents may show different phenotypes compared to the corresponding genetic phenotype in the human disease condition (Jacks, 1996) . For example, nine different tumor suppressor genes associated with human tumors were mutated in mouse and rat. Two mutated genes represented the human phenotype, five mutated genes showed a different spectrum of tumors, and two mutated genes did not show any tumors in rodents (Jacks, 1996) . These studies show that genetic phenotypes in animal models may or may not represent the human disease phenotype.
Considering the above issues, regarding the poor activity of BACE 1 and knockout of BACE 1 in the context of knockout of other genes, we searched for other bsecretase candidate(s) in the brain.
Cathepsin D displays BACE 1-like specificity as b-secretase: their properties indicate the need to search for additional b-secretase candidate(s)
The Schechter group searched for b-secretase in brain utilizing assays of b-secretase activity with peptide substrates containing the wild-type and mutant Swedish b-secretase site sequences. b-Secretase activity was purified from brain extracts (bovine) and identified as cathepsin D. Although early studies implicated cathepsin D in Alzheimer's disease (Ladror et al., 1994; Cataldo et al., 1995) , the finding that knockout of the cathepsin D gene in mice did not affect Ab formation (Saftig et al., 1996) abolished interest in cathepsin D. However, in consideration of the relevance or irrelevance of animal gene knockout studies to the human genetic disease phenotype, further studies of cathepsin D were warranted. Thus, we studied the properties of cathepsin D compared to BACE 1 that were not examined in prior studies (Schechter and Ziv, 2008) . The kinetic constants k cat /K m for cleaving b-secretase sites of peptides with the Swedish mutant and wild-type sequences by cathepsin D and BACE 1 were determined (Table 1) . Results showed that human BACE 1 and cathepsin D have similar kinetic constants, cleaving the Swedish mutant b-secretase site more efficiently than the wild-type sequence. Gel filtration experiments of brain extracts revealed b-secretase activity at the position of cathepsin D (42 kDa) but not at that of BACE 1 (72 kDa). Pepstatin A at 20 nM completely inhibits the cleavage of peptide substrates with the Swedish mutant b-site by both cathepsin D and brain extracts, while BACE 1 activity on the same peptides is not inhibited by 1000-fold higher concentration of pepstatin A (20 mM).
Quantitative Western blots show that in human brain cathepsin D is approximately 280-fold more abundant than BACE 1. Therefore, it is conceivable that b-secretase activity observed in brain extracts may be primarily due to cathepsin D and not BACE 1.
Nevertheless, since both BACE 1 and cathepsin D show poor kinetic activity towards the wild-type b-secretase site sequence (Table 1) , it is necessary to continue the search for additional b-secretase candidate(s) for cleaving the wild-type b-secretase site (Schechter and Ziv, 2008) . 
Ab production in the regulated secretory pathway of neurons
Neurons possess two distinct secretory pathways consisting of the regulated secretory pathway for activitydependent secretion, and the constitutive secretory pathway for continuous basal secretion (Seidah et al., 1994; Zhou et al., 1999; Thomas, 2002; Fugere and Day, 2005) (Figure 1) . Different proteolytic mechanisms occur in the two secretory pathways (Docherty and Steiner, 1982; Gumbiner and Kelly, 1982; Gainer et al., 1985; Benjannet et al., 1997; Gensberg et al., 1998; Lodish et al., 1999; Thomas, 2002; Hook et al., 2004) , and thus it is important to define the primary secretory pathway(s) involved in Ab production for elucidation of the major proteases that generate secreted Ab, which accumulates in amyloid plaques of AD brains. Such studies indicate that regulated secretion of Ab from brain neurons in vivo produces most of the secreted Ab (Nitsch et al., 1992 (Nitsch et al., , 1993 Farber et al., 1995; Efthimiopoulos et al., 1996; Jolly-Tornetta et al., 1998; Hook et al., 2002 Hook et al., , 2005 Cirrito et al., 2005) . Therefore, b-secretase was studied in regulated secretory vesicles that contain Ab.
Cleavage site-specific assay for cleaving the wildtype b-secretase site leads to identification of cathepsin B in regulated secretory vesicles for Ab production
In search of endogenous protease activity for cleaving the wild-type b-secretase site, a cleavage site-specific assay was developed with the Z-Val-Lys-Met-xMCA The average k cat /K m value for cleaving WT peptide substrates by BACE 1, calculated from data in Table 1. substrate that mimics the P1 to P3 residues of the wildtype b-secretase site. This peptide-MCA substrate monitors b-secretase activity by proteolytic production of fluorescent MCA (methylcoumarinamide). The Z-Val-LysMet-xMCA cleaving activity in regulated secretory vesicles, purified from neuronal-like chromaffin cells, showed a pH optimum of approximately pH 5.5-6.0 that is consistent with the acidic intravesicular environment (Hook et al., 2002) . Moreover, its activity required reducing conditions, which mimics the in vivo reducing environment of secretory vesicles (Hook et al., 2002) . The Z-Val-LysMet-xMCA cleaving activity was represented by cysteine protease activity, since it was inhibited by E64c (Hook et al., 2002) . The Z-Val-Lys-Met-xMCA cleaving activity was purified from the RSVs by a series of chromatographic purification steps. Identification of the enzyme was facilitated by use of the activity-based probe, DCG-04, that detects active cysteine proteases by irreversible binding to the active site (detected by avidin-biotin) (Hook et al., 2005) . Peptide sequencing of the purified enzyme revealed its identity as the cysteine protease cathepsin B (Hook et al., 2005) . Immunoelectron microscopy confirmed the localization of cathepsin B within regulated secretory vesicles (Hook et al., 2005) . In contrast with the known function of cathepsin B in lysosomes for protein degradation (Mort, 2004) , these findings indicate the secretory vesicle as a new subcellular site for a biological function of cathepsin B.
Notably, inhibition of cathepsin B with cysteine protease inhibitors substantially reduced Ab production in the isolated RSVs (Hook et al., 2005) . Ab40 production was reduced by the highly selective cathepsin B inhibitor CA074 (Towatari et al., 1991) , as well as by the general cysteine protease inhibitor E64c (Towatari et al., 1991) . Treatment of chromaffin cells in primary culture with CA074Me, the-cell permeable form of CA074, also resulted in reduced amounts of Ab produced in the regulated secretory pathway (but not the constitutive secretory pathway) (Hook et al., 2005) . In addition, the inhibitor lowered cellular levels of CTFb derived from APP cleavage by b-secretase, suggesting that b-secretase activity was inhibited. These findings indicate cathepsin B as a novel b-secretase in the regulated secretory pathway for production of secreted Ab.
Kinetic properties of cathepsin B demonstrate its preference for the wild-type b-secretase site, rather than the Swedish mutant b-secretase site
Kinetic studies demonstrated the high activity and preference of cathepsin B for cleaving the wild-type b-secretase site, but not the Swedish mutant b-secretase site (Table 2) (Hook et al., 2008 , indicating that cathepsin B efficiently cleaves the wild-type b-secretase substrate with high turnover of substrate to product.
However, cathepsin B showed very low activity with the Swedish mutant b-secretase substrate Z-Val--Asn -xMCA (mutant residues underlined). This finding is Leu in marked contrast to BACE 1, which shows a preference for the Swedish mutant and not the wild-type b-secretase substrate. These biochemical kinetic studies demonstrate the high preference of cathepsin B for the wild-type b-secretase site, rather than the Swedish mutant site of APP. Significantly, the wild-type b-secretase site is relevant to the majority of the AD population, which expresses wild-type APP.
Animal models that express the wild-type b-secretase site of APP for inhibitor studies
The guinea pig and a transgenic mouse model of AD expressing human APP with the wild-type were used to evaluate the effects of cathepsin B inhibitors on Ab production. The guinea pig expresses APP with the wildtype b-secretase site that generates Ab, which is identical to the primary sequence of human Ab (Johnstone et al., 1991; Beck et al., 1997 Beck et al., , 2003 . Transgenic AD mice expressing human APP containing the wild-type b-secretase site, with the London mutation near the gsecretase site (London APP mice), overproduce Ab in amyloid plaques and develop memory deficit (Moechars et al., 1999; Dewachter et al., 2000) . The preference of cathepsin B for cleaving the wild-type b-secretase site predicted that cathepsin B inhibitors would be effective in these animal models expressing APP containing the wild-type b-secretase site, but not those expressing APP with the Swedish mutant b-secretase site. This prediction was tested with animal models expressing wild-type and Figure 3 In vivo administration of CA074Me or E64d reduces brain Ab and CTFb in the guinea pig. E64d or CA074Me were administered by constant i.c.v. infusion into guinea pig brains by Alzet minipumps for 7 days or 30 days. Brain extracts were prepared and total Ab (Ab40 and Ab42) were measured by ELISA assays. (A) E64d reduces brain Ab levels. E64d treatment for 7 or 30 days reduced the total Ab by 31% and 55% relative to control, respectively (diagonal striped bars). Results are shown as mean"SEM (pg/mg protein), with *indicating a significant difference from controls (p-0.05, Student's t-test). (B) CA074Me reduces brain Ab levels. In vivo CA074Me treatment for 7 or 30 days reduced total Ab by 57% and 62% relative to control, respectively (solid bars). After 7 days of treatment, CA074Me significantly reduced total Ab. Data are shown as mean"SEM (pg/mg protein), with *indicating a significant difference from controls (p-0.05, Student's t-test).
Swedish mutant b-secretase sites of APP (Hook et al., 2007a (Hook et al., ,b, 2008 .
Inhibitors of cathepsin B reduce Ab in guinea pig brains
In vivo studies in guinea pigs demonstrated significant reduction of Ab in brain by inhibitors of cathepsin B consisting of CA074Me (prodrug form of the selective cathepsin B inhibitor, CA074), E64d (the ester prodrug of its biologically active acid form, E64c) (Tamai et al., 1986) , and acetyl-L-leucyl-L-valyl-L-lysinal (Ac-LVK-CHO) (McConnell et al., 1993) . Administration (i.c.v.) of E64d or CA074Me resulted in substantial reductions of Ab40 and Ab42 by 50-70% after 7 or 30 days of treatment ( Figure  3) , and similar reductions of these Ab peptides resulted after treatment with Ac-LVK-CHO (Hook et al., 2007a,b) . The inhibitor treatments also reduced CTFb, suggesting that the inhibitors reduced b-secretase activity. Moreover, the inhibitor treatment reduced Ab levels in brain synaptosomes, which are enriched with RSVs thus indicating inhibition of Ab production in the regulated secretory pathway of brain neurons (Hook et al., 2007b) . These data demonstrate the in vivo effectiveness of cathepsin B inhibitors to reduce brain Ab levels produced by cleavage of the wild-type b-secretase site of APP in the regulated secretory pathway.
Inhibitors of cathepsin B improve memory and reduce Ab in transgenic AD mice that express the wild-type, but not the Swedish mutant, b-secretase site of APP In the London APP transgenic mouse model of AD that expresses human APP with the wild-type b-secretase site, administration of E64d or CA074Me for 30 days significantly improved the memory deficit (measured by the Morris water maze test) and reduced brain amyloid plaque (Hook et al., 2008) . These inhibitors improved memory by approximately 50%, which approached the normal level of memory function in non-transgenic agematched controls ( Figure 4A ). Each inhibitor treatment also reduced brain amyloid plaque load by approximately 50% and reduced brain Ab by approximately 40-50% ( Figure 4B ). Furthermore, the reduction of CTFb by these inhibitors indicated inhibition of b-secretase activity.
In contrast, inhibitors of cathepsin B had no effect in a transgenic AD mouse model expressing the Swedish mutant b-secretase site of APP (Hook et al., 2008) . In London APP mice that also express the Swedish mutation (Swedish/London APP), treatment with E64d or CA074Me had no effects on memory, brain amyloid plaque, brain Ab, or CTFb. The in vivo effects of these cathepsin B inhibitors mirrored their in vitro cleavage specificity for the wild-type b-secretase site compared to the Swedish mutant b-secretase site. These data support the hypothesis that cathepsin B possesses selectivity for cleaving the wild-type b-secretase site, rather than the Swedish mutant site of APP, for production of neurotoxic Ab peptides. Importantly, cathepsin B cleavage of the wild-type b-secretase site is relevant to the majority of the AD population that expresses wild-type APP.
The function of cathepsin B as b-secretase is not precluded by BACE 1 knockout mouse results
Results presented by the Hook group, combined with knowledge in the field, suggest that cathepsin B and BACE 1 both function as b-secretase enzymes. While BACE 1 has been proposed to be the major b-secretase based on BACE 1 knockout experiments (Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001; Vassar, 2004) , detailed assessment of the BACE 1 knockout studies indicate that they do not preclude cathepsin B as a bsecretase for the wild-type b-secretase site in the regulated secretory pathway.
Roberds et al. describe that BACE 1 knockout mice lack b-secretase activity, but the assays in which the bsecretase activity was assayed contained E64, a potent inhibitor of cysteine proteases, which precluded detection of cathepsin B b-secretase activity in the assay (Roberds et al., 2001 ). Thus, Roberds et al. do not rule out cathepsin B as a b-secretase. (i.c.v.) to the London APP mice that express human APP with the wild-type b-secretase site and a mutation near the g-secretase site. The constant i.c.v. administration into the brain utilized Alzet minipumps for 28 days. Mice were then evaluated for the status of memory by the Morris water maze test; the latency period measures the time required for the animal to swim to a submerged platform after training to learn of the platform location, with shorter times reflecting improved memory. The mean latency times and percent standard errors (% SEM) are shown for the control (vehicletreated), CA074Me-treated, and E64d-treated London APP animals. The statistical significance between the means for the London APP animals of each treated group and the control is indicated (***p-0.0001, Student's t-test). The mean latency period for untreated wild-type, strain-matched, non-transgenic mice is shown as a dashed line. Thus, the CA074Me and E64d treatments significantly shortened the latency period by 42% and 53%, respectively, relative to the London APP controls and restored approximately 68% and 86%, respectively, of the memory of wild-type non-transgenic mice. (B) Inhibitors of cathepsin B reduce amyloid plaque load in the London APP mice. Reduction of total amyloid plaque load occurred in brains after treatment of London APP mice with CA074Me or E64d inhibitors. After treatment with these inhibitors (as described in previous paragraph), amyloid plaques in brain were revealed by anti-Ab immunohistochemistry of brain sections. Quantitation of relative amyloid plaque load in the entire brain section was achieved by computer image analyses, expressed as percent of the tissue area. The relative amyloid loads are displayed as the mean (% tissue area) and SEM. Statistical significance between each inhibitor-treated group and control is indicated (***p-0.0001, Student's t-test). Inhibitor treatments reduce the plaque load by approximately 45%. Luo et al. found that knocking out BACE 1 in mice expressing human APP containing the Swedish mutant b-secretase site resulted in no Ab or C99 production (CTFb) (Luo et al., 2001 ). However, this study did not evaluate wild-type b-secretase site cleavage. Thus, Luo et al. do not rule out cathepsin B cleavage of APP containing the wild-type b-secretase site.
Cai et al. found that 'conditioned media' lacked Ab from embryonic brain neurons of BACE 1 knockout animals expressing APP containing the wild-type b-secretase site (Cai et al., 2001) . However, the 'conditioned media' reflected only constitutive secretion, because the neurons were not stimulated with a triggering agent and, therefore, no regulated secretion occurred. Thus, Cai et al. do not exclude cathepsin B b-secretase activity in the regulated secretory pathway.
Taken together, the knockout BACE 1 experiments do not address cysteine protease b-secretase cleavage of APP containing the wild-type b-secretase site in the regulated secretory pathway. Therefore, cathepsin B bsecretase activity can be reconciled with BACE 1 knockout data, because that data does not rule out cathepsin B as a possible b-secretase.
Interestingly, a recent study examined the role of BACE 1 on endogenous in vivo levels of Ab in brain to address mechanisms for Ab production in sporadic AD, where there is no overexpression of APP (Hirata-Fukae et al., 2008) . In adult mice, overexpression of BACE 1, by approximately 12-fold greater than that expressed in wild-type mice, did not result in elevated endogenous Ab. Thus, factors other than BACE 1 must be involved in Ab production in adult and aging brain, and such factors may provide therapeutic targets. These findings are consistent with the proposal for cathepsin B as a candidate b-secretase for production of Ab in adult conditions (Hook et al., 2007a (Hook et al., ,b, 2008 .
Inhibitors of cathepsin B as potential therapeutic agents for Alzheimer's disease
Key findings from studies of cathepsin B in regulated secretory vesicles for the cleavage of the wild-type bsecretase site of APP indicate cathepsin B as a newly identified drug target for AD. The notable efficacy of the CA074Me and E64d inhibitors to improve memory and reduce Ab in an AD animal model expressing the wildtype b-secretase APP site present in the majority of AD patients provides support for these inhibitors as potential AD therapeutic agents. The spontaneously occurring chemical rearrangement of asparagines or aspartate residues depends on the structure of the adjacent C-terminal amino acid. It proceeds very fast if Asp is followed by small aliphatic amino acids, such as Gly, Ser or Ala (half-times of minutes). The majority of the isoAsp residues have been found on the protein surface, since the more rigid protein core prevents this intramolecular reaction. The enzyme peptidyl-isoaspartyl methyltransferase can convert only within a peptide chain isoAsp back into Asp (Clarke, 2003) .
Ab(1-40/42) are highly abundant in AD amyloid depositions. They can make up over 50% of all Ab found, depending on the particular tissue (Shimizu et al., 2005) . The formation of isoAsp within a peptide chain is a chemically spontaneously occurring process during aging of proteins (for a recent review see Shimizu et al., 2005) . Aspartic acid (Asp) or asparagine (Asn) residues within a peptide chain can undergo intramolecular cyclization with release of water or ammonia, respectively ( Figure 5 ). The generated metastable succinimide spontaneously decomposes to yield L-isoAsp, L-Asp and D-isoAsp and D-Asp in an approximate ratio of 70:20:5:5 (Vigneswara et al., 2006) . The tendency to form the intramolecular succinimide depends markedly on the amino acids located at the C-terminal side of the Asp/Asn residue. It was found that the velocity of isoAsp formation is much faster if small amino acids (e.g., glycine, histidine, serine or alanine) are located at this position (Galletti et al., 1995) . The formation of isoAsp introduces an additional methylene group in the peptide backbone, which could alter the structure and function of proteins. Moreover, this change in the peptide backbone could affect the susceptibility of the proteins for cleavage by proteases as demonstrated for prolyl endopeptidase or the proteasome (Tarcsa et al., 2000) .
To address , but, in contrast, BACE 1 did not cleave that substrate at all (Table 3) . Moreover, the cathepsin B inhibitor, Ac-LVK-CHO, inhibited cleavage of the wild-type bsecretase substrate by cell extracts, whereas the BACE 1 inhibitor KTEEISEVN(Statine)VAEF had no effect. These data suggest the possibility that cathepsin B, rather than BACE 1, produces isoAsp-Ab in AD patients by cleaving the wild-type b-secretase site containing isoAsp (Bö hme et al., submitted) .
Further evaluation of b-secretase activities utilized longer, more structured peptides, consisting of unlabeled 27 amino acid long peptides Ac-EEISE VKM(NL) D( AEF RHDSG YEVHH QKLVF-NH 2 covering the isoD) b-cleavage site from amino acid -8 to 19 (Ab numbering, corresponding to APP 664-690), were synthesized. Hydrolysis of these peptides by BACE-1, cathepsin B and SH-SY5Y cell extracts was analyzed by matrixassisted laser desorption and ionization time-of-flight mass spectrometry Bö hme et al., submitted) . The incubation of the peptides with BACE-1 for up to 24 h supported the findings obtained with the 12 amino acids long internally quenched fluorescent peptide substrates. A cleavage pattern characteristic for BACE-1 (prior to Asp1) could only be observed in the case of the SW peptide (-LxD-). This hydrolysis was abolished during co-incubation of peptide, BACE-1 and the specific BACE-1 inhibitor. However, the isoAsp-containing 27 amino acid long peptides are not cleaved by BACE-1, but in contrast, cathepsin B hydrolyses the isoAsp containing substrates even more readily than the L-Asp containing variants. Incubating the peptides with neuroblastoma cell extract resulted in a cleavage pattern that was basically the same as with the purified enzymes, and substrate cleavage could be blocked by the cathepsin B inhibitor Ac-LVK-CHO (Bö hme et al., submitted). Similar as with the 12 amino acid long peptides, cathepsin B cleavage occurred within the longer peptides preferentially after position P2 of the substrates which Table 3 Kinetic parameters of BACE 1 and cathepsin B hydrolysis of peptides containing the wildtype (WT) b-secretase cleavage site, with and without the chemical isoAsp modification (WT-iso). corresponds to penultimate amino acid of the Asp or isoAsp-linkage (i.e., in wild-type at -KxMDA-or -Kx MisoDA-and in the Swedish sequences at -NxLDA-or -NxLisoDA-). This cleavage pattern clearly differentiates the cathepsin B mediated hydrolysis of APP-like substrates from the known BACE 1-mediated APP hydrolysis. The data clearly corroborate the results obtained by Hook et al. (2005) and by Schechter and Ziv (2008) . However, in contrast to BACE 1 and cathepsin D, the turnover of longer substrates by cathepsin B takes place not at the common APP 672 cleavage site. Moreover, posttranslational modifications, such as the isoAsp formation, which is highly abundant in APP as well as in deposited Ab in AD, even augment the unexpected cathepsin B cleavage pattern. In fact, this could be one reason for the different metabolic fate of APP leading to further N-terminal truncated and modified, neurotoxic Ab peptide species, such as pyroGluAb (Russo et al., 2002; Cynis et al., 2006 .
Truncated pyroGluAb(3-40/42) peptide forms in senile plaques of AD brains
Initial studies of Ab peptide forms in AD brains identified Ab(1-40) and the C-terminally extended Ab(1-42) peptide forms of Ab in amyloid plaques (Saido et al., 1995 (Saido et al., , 1996 . In addition to differences in C-termini of Ab forms, N-terminal peptide heterogeneity represents a significant portion of Ab in AD brains. Interestingly, a greater number of plaques positive with antibodies directed to pGluAb(3-40/42) were observed in AD compared to normal age-matched brains. These data suggest that the deposition of pGluAb(3-40/42) may precede that of Ab(1-40/42).
Notable results were obtained from analyses of the seeding of Ab peptides to form oligomers, showing that the pGlu-modified Ab peptides accelerated initial acceleration of aggregate formation by up to 250-fold compared to unmodified Ab . Furthermore, results suggested that pGlu-modified Ab peptides promote seeding of mixed Ab peptide aggregates. These biophysical characteristics of pGlu-amyloid peptides may be crucial for the initial development of AD.
Glutaminyl cyclase mediates N-terminal pGlu cyclization to generate pGluAb(3-40/42) N-terminal pGlu modification of Ab(3-40/42) by glutaminyl cyclase is predicted to generate pGluAb(3-40/42) ( Figure 6 ). Inhibition of glutaminyl cyclase reduces formation of pGluAb(3-42) thus revealing the importance of glutaminyl cyclase activity for maturation of cellular pGlucontaining Ab peptides (Schilling et al., 2004; Cynis et al., 2006) .
Recent in vivo studies showed that administration of a glutaminyl cyclase inhibitor prevented the formation of pGlu-containing Ab peptides in brains of rats, as well as in a transgenic mouse model of AD. Importantly, the glutaminyl cyclase inhibitor improved memory during reduction of pGluAb peptides. These findings implicate the importance of glutaminyl cyclase in catalyzing the production of neurotoxic pGlu-modified Ab peptides .
Evidence that formation of pGlu-Ab peptides prefers utilization of the b-secretase pathway derived from wild-type APP rather than the Swedish mutant APP Because formation of N-terminally truncated pGluAb(3-42) may be a key event in the development of AD, it is important to understand cellular mechanisms that generate these forms of Ab from APP. Recent experiments have compared the formation of pGluAb(3-40/42) and Ab(1-40/42) from wild-type and Swedish mutant APP forms by expression in cells (HEK293 cell line).
Results showed that a larger amount of pGluAb(3-40/42) was produced from wild-type human APP and human London APP, both of which express the wild-type bsecretase site. However, a larger amount of Ab(1-40/42) was generated from Swedish mutant APP or Swedish/ London APP, both of which possess the Swedish mutant b-secretase site. Furthermore, production of pGluAb(3-40/42) from wild-type APP was not reduced by an inhibitor of BACE 1. These findings suggest that a bsecretase other than BACE 1 participates in the formation of pGluAb(3-40/42) from wild-type APP. Based on the studies of this article describing a role for cathepsin B in Ab production utilizing the wild-type b-secretase site of APP, it will be of interest in future studies to examine the possibility that cathepsin B may be involved in the production of pGlu forms of Ab (Cynis et al., , 2008 .
Summary
In this paper we have summarized the work presented by three independent groups at the 5 th General Meeting of the IPS on potential AD drug targets. The combined data support the existence of b-secretases other than BACE 1 and provide evidence for novel enzymatic pathways mediated by cathepsin B as b-secretase and glutaminyl cyclase production of pGlu-modified forms of Ab. BACE 1 and the more abundant cathepsin D cleave the wild-type b-secretase site with low efficacy. Notably, cathepsin B specifically and efficiently cleaves the wildtype b-secretase site present in the majority of AD patients. Subsequent to such a cathepsin B b-secretase step, glutaminyl cyclase modification of truncated Ab(3-40/42) can generate modified pGluAb(3-40/42). These findings provide evidence for cathepsin B and glutaminyl cyclase as potential new drug targets to inhibit production of multiple Ab peptide forms in AD.
